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Group B Streptococcus in Pregnancy
Lindsay Doyle MSN, RN
Introduction
• Group B Streptococcus (GBS) is a 
bacterium present in the vaginal 
and/or anorectal flora of women 
and is considered to be normal 
flora which generally does not 
cause infection; however, if a 
pregnant woman is GBS positive 
and left untreated during birth, 
the newborn passing through 
the birth canal is at risk for 
becoming colonized (Bicheno & 
Geraghty, 2015, p. 224).
• GBS is the “leading infectious 
cause of neonatal morbidity and 
mortality in the United States” 
(Colicchia, Lauderdale, Du, 
Adams, & Hirsch, 2015, p. 173).
• Up to 30% of pregnant women 
carry GBS bacteria in their lower 
gastrointestinal or genitourinary 
tract and up to 1% of neonates 
born to colonized mothers 
become infected in utero or 
during delivery (Fabbrini et al., 
2018).
Maternal Risk Factors 
that Increase Chance 
of Transmitting GBS to 
Infant:
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• “Women who colonize GBS may be 
asymptomatic in pregnancy.  It is 
possible, however, for women to 
become unwell in the postnatal 
period. Infections caused by GBS 
colonization can include urinary tract 
infections, endometritis, wound 
infections, puerperal sepsis, 
meningitis, and septic 
thrombophlebitis” (Bicheno & 
Geraghty, 2015, p. 225).
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Signs and Symptoms
Neonates
• Neonates exposed to GBS, “may 
develop symptoms of rapidly 
invasive disease including sepsis, 
pneumonia, and meningitis within 
the first week after birth (early-
onset disease) or after a week and 
up to three months of life (late-
onset disease)” (Kawa, 2017, p. 20).
• Infants can become ill with early-
onset GBS disease from either 
aspirating or ingesting of GBS 
positive amniotic fluid during birth, 
which could “cause the neonate to 
experience a variety of signs and 
symptoms, which include low 
temperature, pyrexia, bradypnea, 
tachypnea, bradycardia, 
tachycardia, appear floppy, have 
the inability to feed, and appear 
pale or irritable” (Bicheno & 
Geraghty, 2015, p. 225).  
• Early-onset GBS disease occurs 
more often and is more fatal than 
late-onset GBS disease (Sheehy, 
Davis, & Homer, 2013).
• Infected infants who survive may 
experience life-long impairments, 
such as deafness, blindness, or 
developmental issues (CDC, 2018).
• Labor or rupture of membranes 
before 37 weeks gestation
• Membrane rupture more than 18 
hours before birth
• Urinary tract infection with GBS 
during pregnancy
• Previous baby with GBS infection
• Fever during labor
• Chorioamnionitis
• Positive culture for GBS colonization 
at 35-37 weeks
(CDC, 2018)
• If a woman who is pregnant tests 
positive for GBS, it is recommended 
that she is treated with penicillin G 
at least four hours before delivery 
(with at least two doses) for 
maximum effectiveness.  If a mom is 
allergic to penicillin G, with a low 
concern for an anaphylaxis reaction, 
then cefazolin is recommended.  If 
there is a risk for an anaphylactic 
reaction, then clindamycin is the 
next option with vancomycin also 
being available if a mom’s culture 
indicates resistance to clindamycin 
(Apgar et al., 2005, p. 903).
• If a woman tests negative for GBS, 
then no antibiotic or treatment is 
necessary.
• If a pregnant carrier of GBS receives 
IV antibiotics during delivery, her 
baby has a 1 in 4,000 chance of 
developing GBS infection.  Without 
antibiotics, her baby has a 1 in 200 
chance of developing GBS infection 
(CDC, 2018).
• The antibiotics used to prevent 
early-onset group B strep disease in 
newborns only help during 
labor. Pregnant women cannot take 
them before labor, because the 
bacteria can grow back quickly (CDC, 
2018).
• GBS samples are collected using a 
single swab technique, where the 
vagina is swabbed first, followed 
by the rectum (Sheehy et al., 
2013).  The GBS cultures take 24 to 
48 hours to result and the results 
are considered valid for five weeks 
(Bicheno & Geraghty, 2015).
• A neonate may be tested and 
diagnosed with GBS from either a 
blood test, urine specimen, or by 
cerebrospinal fluid (Bicheno & 
Geraghty, 2015, p. 225). 
• GBS status can be variable 
between pregnancies and even 
transient during a given 
pregnancy, so the mother must be 
tested each pregnancy (Colicchia 
et al., 2015).
• Health care providers need to be 
vigilant about screening for GBS in 
pregnancy.  All women who are 
pregnant should be tested for GBS 
at 35 to 37 weeks’ gestation in each 
pregnancy (Zolotor & Carlough, 
2014).  
• Individuals who have a history of 
preterm labor or exhibit signs of 
preterm labor, may need to be 
tested sooner or every five weeks 
for GBS.  
• When caring for a neonate, the 
health care provider should review 
maternal testing to ensure that the 
GBS result for the mother was 
obtained and she was treated 
during labor.
• GBBS positive may be spread from 
infant to infant if precise 
handwashing technique is not used 
when handling newborns
In conclusion, GBS screening and 
treatment will ‘facilitate early 
detection and antibiotic treatment 
that will decrease the probability of 
neonatal infection, thereby reducing 
damage, regrets, and medical 
expenditure” (Hung et al., 2018, p. 2).  
All women should be screened for 
GBS at prenatal appointments since a 
GBS vaccine is not yet available 
(Fabbrini et al., 2018).  By screening 
women at prenatal appointments for 
GBS, it could help prevent infants 
from contracting early-onset GBS or 
late-onset GBS disease and possibly 
preventing the infants from death or 
life-long disabilities.  Antibiotic 
administration during labor to 
pregnant women colonized with GBS 
can help prevent the transmission of 
GBS infection, and thus decrease the 
incidence of early and late onset GBS 
disease in newborns.
Figure 1. Incidence of early-onset and late-onset invasive GBS 
disease and activities of prevention of GBS disease (Verani, McGee, 
& Schrag, 2010).
• The process of neonatal infection by GBS is complex and multifactorial.  “Host 
factors play a central role in determining the pathogenic potential of GBS, but 
bacterial virulence factors also assist GBS in the pathogenesis within the host” 
(Melin, 2011, p. 1296).  
• “The first stage in the pathogenesis of GBS is the establishment of vaginal 
colonization in the pregnant woman including adherence to vaginal epithelial 
cells and resistance to mucosal immune defenses.  To gain access to the fetus, 
GBS may ascend into the amniotic cavity.  Bacterial proliferation allows GBS to 
colonize the skin or mucous membranes of the fetus or to enter the fetal lung 
through aspiration of infected amniotic fluid.  After birth, GBS must successfully 
replicate within the alveoli of the neonate, adhere to respiratory epithelium and 
avoid clearance by pulmonary macrophages.  Pneumonia with lung cell injury is 
characteristic of GBS and may be mediated in part by the cytotoxic properties of 
GBS…and the influx of host neutrophils.  The invasion by GBS of the pulmonary 
epithelial and endothelial cells may allow GBS to enter the bloodstream causing 
septicemia.  This blood stream dissemination may lead to meningitis and 
osteomyelitis.  This disease progression indicates that GBS has to evade the 
host’s natural immune defenses to adhere, to invade, and to transcytose several 
cell barriers” (Melin, 2011, p. 1296-1297).
GBS is an encapsulated gram-positive diplococcus frequently found in the human 
gastrointestinal or lower genital tract (Cho, et al., 2017).  The significance of GBS can be 
devastating on an infant if not correctly detected or treated on a GBS positive mother as 
GBS is the leading cause of neonatal sepsis and meningitis, which could lead to death 
(Melin, 2011).  GBS can also cause invasive bacterial infections and pneumonia during the 
first week of life (Melin, 2011).  Infants that survive GBS meningitis have a 50% chance of 
having long-term impairments and up to 30% have severe neurological deficits (Melin, 
2011).  Per Melin (2011), about 30-70% of neonates born to GBS positive mothers become 
transiently colonized by their mother’s organism.  Most of them remain asymptomatic, but 
among these infants 1-3% develop a severe disease from the GBS (Melin, 2011, p. 1295).
Figure 2. Recommended intrapartum antibiotic regimen 
(Verani, McGee, & Schrag, 2010)
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